Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：454頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Non-Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Non-Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Non-Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Non-Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Non-Hodgkin Lymphoma Overview 13
Therapeutics Development 14
Pipeline Products for Non-Hodgkin Lymphoma - Overview 14
Pipeline Products for Non-Hodgkin Lymphoma - Comparative Analysis 15
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 16
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 23
Non-Hodgkin Lymphoma - Pipeline Products Glance 25
Late Stage Products 25
Clinical Stage Products 26
Early Stage Products 27
Unknown Stage Products 28
Non-Hodgkin Lymphoma - Products under Development by Companies 29
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 35
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Boehringer Ingelheim GmbH 37
F. Hoffmann-La Roche Ltd. 38
Biogen Idec Inc. 39
Amgen Inc. 40
Sanofi 41
Eli Lilly and Company 42
Seattle Genetics, Inc. 43
Genentech, Inc. 44
Gilead Sciences, Inc. 45
Merck & Co., Inc. 46
Gamida Cell Ltd. 47
BioLineRx, Ltd. 48
Celltrion, Inc. 49
ZIOPHARM Oncology, Inc. 50
Millennium Pharmaceuticals, Inc. 51
Novartis AG 52
Astellas Pharma Inc. 53
Eisai Co., Ltd. 54
Richter Gedeon Nyrt. 55
ImmunoGen, Inc. 56
Pfizer Inc. 57
Sigma-Tau S.p.A. 58
Astex Pharmaceuticals, Inc. 59
Cell Therapeutics, Inc. 60
Celgene Corporation 61
Bayer AG 62
Immunomedics, Inc. 63
Idera Pharmaceuticals, Inc. 64
TG Therapeutics, Inc. 65
Curis, Inc. 66
Accentia Biopharmaceuticals, Inc. 67
Portola Pharmaceuticals, Inc. 68
Mundipharma International Limited 69
Pharmacyclics, Inc. 70
Dynavax Technologies Corporation 71
MorphoSys AG 72
BioInvent International AB 73
Xenetic Biosciences plc 74
Takara Bio Inc. 75
Panacea Biotec Limited 76
Transgene Biotek Limited 77
Spectrum Pharmaceuticals, Inc. 78
Affimed Therapeutics AG 79
CIMAB S.A. 80
Supratek Pharma Inc. 81
Memgen, LLC. 82
Actinium Pharmaceuticals, Inc. 83
Agios Pharmaceuticals, Inc. 84
ProNAi Therapeutics, Inc. 85
Grupo Ferrer Internacional, S.A. 86
Onconova Therapeutics, Inc. 87
Kainos Medicine, Inc. 88
Acetylon Pharmaceuticals, Inc. 89
Taiwan Liposome Company, Ltd. 90
Xcovery, Inc. 91
Pharma Mar, S.A. 92
Bellicum Pharmaceuticals, Inc. 93
Biothera, Inc. 94
Sigma-Tau Pharmaceuticals, Inc 95
EpiZyme, Inc. 96
NuCana BioMed Limited 97
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 98
Biosidus S.A. 99
Otsuka Holdings Co., Ltd. 100
Polaris Group 101
Fountain Biopharma Inc. 102
Karyopharm Therapeutics, Inc. 103
Inbiopro Solutions Pvt. Ltd. 104
Conkwest, Inc. 105
International Biotechnology Center Generium 106
Oncobiologics, Inc. 107
Mission Therapeutics Ltd 108
bioXPRESS Therapeutics SA 109
Avipep Pty Ltd 110
Nordic Nanovector AS 111
Biocad 112
Tolero Pharmaceuticals, Inc. 113
Innovent Biologics, Inc. 114
AbbVie Inc. 115
AlphaMab Co., Ltd 116
Amgen Astellas BioPharma K.K. 117
Non-Hodgkin Lymphoma - Therapeutics Assessment 118
Assessment by Monotherapy Products 118
Assessment by Target 119
Assessment by Mechanism of Action 126
Assessment by Route of Administration 134
Assessment by Molecule Type 137
Drug Profiles 140
dasiprotimut T - Drug Profile 140
procarbazine hydrochloride - Drug Profile 142
rituximab - Drug Profile 143
pixantrone dimaleate - Drug Profile 146
StemEx - Drug Profile 150
obinutuzumab - Drug Profile 152
vincristine sulfate liposomal - Drug Profile 154
lenalidomide - Drug Profile 157
PGG beta-glucan - Drug Profile 160
rituximab biosimilar - Drug Profile 164
veltuzumab - Drug Profile 165
bendamustine - Drug Profile 168
alvocidib hydrocholride - Drug Profile 170
blinatumomab - Drug Profile 171
brentuximab vedotin - Drug Profile 174
mocetinostat - Drug Profile 179
agatolimod sodium - Drug Profile 182
forodesine hydrochloride - Drug Profile 185
ISF-35 - Drug Profile 187
Oncohist - Drug Profile 189
MOR-208 - Drug Profile 191
plitidepsin - Drug Profile 192
copanlisib - Drug Profile 194
atorvastatin calcium - Drug Profile 197
epratuzumab - Drug Profile 198
CTL-019 - Drug Profile 203
pegargiminase - Drug Profile 205
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes - Drug Profile 208
PNT-2258 - Drug Profile 210
GS-9973 - Drug Profile 212
BL-8040 - Drug Profile 213
Iomab-B - Drug Profile 215
abexinostat hydrochloride - Drug Profile 217
dasatinib - Drug Profile 219
IMMU-110 - Drug Profile 222
CC-223 - Drug Profile 224
CD19CAR/Virus Specific T Cells - Drug Profile 225
PRT-2070 - Drug Profile 226
BPX-501 - Drug Profile 227
Betalutin - Drug Profile 228
E-7438 - Drug Profile 230
Minor Histocompatibility Antigen - Drug Profile 232
Chimeric Anti-CD20 Monoclonal Antibody - Drug Profile 233
alisertib - Drug Profile 234
pictilisib - Drug Profile 237
vinorelbine tartrate liposomal - Drug Profile 239
AT-9283 - Drug Profile 241
AT-7519 - Drug Profile 243
SAR-650984 - Drug Profile 246
BI-2536 - Drug Profile 248
SD-101 - Drug Profile 250
darinaparsin - Drug Profile 252
briciclib sodium - Drug Profile 254
IMMU-114 - Drug Profile 255
X-396 - Drug Profile 256
EBV-Specific T-Lymphocytes - Drug Profile 257
LY-2780301 - Drug Profile 259
OPB-51602 - Drug Profile 260
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 261
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 262
alefacept - Drug Profile 263
rituximab biosimilar - Drug Profile 264
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 266
pembrolizumab - Drug Profile 267
PF-05082566 - Drug Profile 269
AMG-319 - Drug Profile 270
IMGN-529 - Drug Profile 271
venetoclax - Drug Profile 272
CC-115 - Drug Profile 275
CC-122 - Drug Profile 276
NUC-1031 - Drug Profile 278
KPT-330 - Drug Profile 280
vincristine sulfate liposomal - Drug Profile 282
Genetically Modified T Cell - Drug Profile 283
TG-1101 + TGR-1202 - Drug Profile 284
LMP-Specific Cytotoxic T Cells - Drug Profile 285
rituximab biosimilar - Drug Profile 286
CST-103 - Drug Profile 287
IMO-4200 - Drug Profile 288
AFM-11 - Drug Profile 290
KML-001 - Drug Profile 291
bendamustine hydrochloride - Drug Profile 293
ricolinostat - Drug Profile 294
rituximab biosimilar - Drug Profile 296
CUDC-907 - Drug Profile 298
AVP-5 - Drug Profile 300
CD19-CAR Gene Therapy - Drug Profile 301
AG-221 - Drug Profile 303
tenatumomab - Drug Profile 305
TBL-0306-L - Drug Profile 306
rituximab biosimilar - Drug Profile 307
FV-162 - Drug Profile 308
Oncology Program - Drug Profile 309
IGN-002 - Drug Profile 310
vinorelbine - Drug Profile 311
rituximab biosimilar - Drug Profile 312
Ritonavir Analogs - Drug Profile 313
FIB-114 - Drug Profile 314
BI-1206 - Drug Profile 315
GNR-022 - Drug Profile 316
FB-811 - Drug Profile 317
rituximab biosimilar - Drug Profile 318
CB-839 - Drug Profile 319
SGN-CD70A - Drug Profile 320
FV-214 - Drug Profile 321
rituximab biosimilar - Drug Profile 322
EPZ-005687 - Drug Profile 323
KN-001 - Drug Profile 325
MN-2 - Drug Profile 326
rituximab biosimilar - Drug Profile 327
Small Molecule for Hematologic Malignancies - Drug Profile 328
KM-301 - Drug Profile 329
IBPM-001-RX - Drug Profile 330
rituximab biosimilar - Drug Profile 331
rituximab biosmiliar - Drug Profile 332
rituximab biosimilar - Drug Profile 333
rituximab biosimilar - Drug Profile 334
Non-Hodgkin Lymphoma - Recent Pipeline Updates 335
Non-Hodgkin Lymphoma - Dormant Projects 434
Non-Hodgkin Lymphoma - Discontinued Products 436
Non-Hodgkin Lymphoma - Product Development Milestones 437
Featured News & Press Releases 437
Appendix 445
Methodology 445
Coverage 445
Secondary Research 445
Primary Research 445
Expert Panel Validation 445
Contact Us 446
Disclaimer 446
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2014 22
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Development by Companies, H1 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2014 32
Comparative Analysis by Late Stage Development, H1 2014 33
Comparative Analysis by Clinical Stage Development, H1 2014 34
Comparative Analysis by Early Stage Development, H1 2014 35
Comparative Analysis by Unknown Stage Development, H1 2014 36
Products under Development by Companies, H1 2014 37
Products under Development by Companies, H1 2014 (Contd..1) 38
Products under Development by Companies, H1 2014 (Contd..2) 39
Products under Development by Companies, H1 2014 (Contd..3) 40
Products under Development by Companies, H1 2014 (Contd..4) 41
Products under Development by Companies, H1 2014 (Contd..5) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 45
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 46
Non-Hodgkin Lymphoma - Pipeline by Biogen Idec Inc., H1 2014 47
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2014 48
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2014 49
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2014 50
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 51
Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2014 52
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 53
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 54
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2014 55
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2014 56
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2014 57
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 58
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 59
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2014 60
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 61
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2014 62
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2014 63
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 64
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2014 65
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2014 66
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 67
Non-Hodgkin Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 68
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2014 69
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2014 70
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 71
Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 72
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2014 73
Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2014 74
Non-Hodgkin Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 75
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 76
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Limited, H1 2014 77
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 78
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2014 79
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2014 80
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2014 81
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H1 2014 82
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2014 83
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2014 84
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2014 85
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 86
Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2014 87
Non-Hodgkin Lymphoma - Pipeline by CIMAB S.A., H1 2014 88
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2014 89
Non-Hodgkin Lymphoma - Pipeline by Memgen, LLC., H1 2014 90
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 91
Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 92
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 93
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 94
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 95
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2014 96
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014 97
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2014 98
Non-Hodgkin Lymphoma - Pipeline by Xcovery, Inc., H1 2014 99
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2014 100
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 101
Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc.., H1 2014 102
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 103
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2014 104
Non-Hodgkin Lymphoma - Pipeline by NuCana BioMed Limited, H1 2014 105
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2014 106
Non-Hodgkin Lymphoma - Pipeline by Biosidus S.A., H1 2014 107
Non-Hodgkin Lymphoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 108
Non-Hodgkin Lymphoma - Pipeline by Polaris Group, H1 2014 109
Non-Hodgkin Lymphoma - Pipeline by Fountain Biopharma Inc., H1 2014 110
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 111
Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 112
Non-Hodgkin Lymphoma - Pipeline by Conkwest, Inc., H1 2014 113
Non-Hodgkin Lymphoma - Pipeline by International Biotechnology Center Generium, H1 2014 114
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics, Inc., H1 2014 115
Non-Hodgkin Lymphoma - Pipeline by Mission Therapeutics Ltd, H1 2014 116
Non-Hodgkin Lymphoma - Pipeline by bioXPRESS Therapeutics SA, H1 2014 117
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H1 2014 118
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector AS, H1 2014 119
Non-Hodgkin Lymphoma - Pipeline by Biocad, H1 2014 120
Non-Hodgkin Lymphoma - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 121
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H1 2014 122
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2014 123
Non-Hodgkin Lymphoma - Pipeline by AlphaMab Co., Ltd, H1 2014 124
Non-Hodgkin Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 125
Assessment by Monotherapy Products, H1 2014 126
Number of Products by Stage and Target, H1 2014 129
Number of Products by Stage and Mechanism of Action, H1 2014 136
Number of Products by Stage and Route of Administration, H1 2014 144
Number of Products by Stage and Molecule Type, H1 2014 147
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 343
Non-Hodgkin Lymphoma - Dormant Projects, H1 2014 442
Non-Hodgkin Lymphoma - Discontinued Products, H1 2014 444
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2014 22
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 33
Comparative Analysis by Clinical Stage Development, H1 2014 34
Comparative Analysis by Early Stage Products, H1 2014 35
Assessment by Monotherapy Products, H1 2014 126
Number of Products by Top 10 Target, H1 2014 127
Number of Products by Stage and Top 10 Target, H1 2014 128
Number of Products by Top 10 Mechanism of Action, H1 2014 134
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 135
Number of Products by Top 10 Route of Administration, H1 2014 142
Number of Products by Stage and Top 10 Route of Administration, H1 2014 143
Number of Products by Top 10 Molecule Type, H1 2014 145
Number of Products by Stage and Top 10 Molecule Type, H1 2014 146
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Non-Hodgkin Lymphoma Overview 13
Therapeutics Development 14
Pipeline Products for Non-Hodgkin Lymphoma - Overview 14
Pipeline Products for Non-Hodgkin Lymphoma - Comparative Analysis 15
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 16
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 23
Non-Hodgkin Lymphoma - Pipeline Products Glance 25
Late Stage Products 25
Clinical Stage Products 26
Early Stage Products 27
Unknown Stage Products 28
Non-Hodgkin Lymphoma - Products under Development by Companies 29
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 35
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Boehringer Ingelheim GmbH 37
F. Hoffmann-La Roche Ltd. 38
Biogen Idec Inc. 39
Amgen Inc. 40
Sanofi 41
Eli Lilly and Company 42
Seattle Genetics, Inc. 43
Genentech, Inc. 44
Gilead Sciences, Inc. 45
Merck & Co., Inc. 46
Gamida Cell Ltd. 47
BioLineRx, Ltd. 48
Celltrion, Inc. 49
ZIOPHARM Oncology, Inc. 50
Millennium Pharmaceuticals, Inc. 51
Novartis AG 52
Astellas Pharma Inc. 53
Eisai Co., Ltd. 54
Richter Gedeon Nyrt. 55
ImmunoGen, Inc. 56
Pfizer Inc. 57
Sigma-Tau S.p.A. 58
Astex Pharmaceuticals, Inc. 59
Cell Therapeutics, Inc. 60
Celgene Corporation 61
Bayer AG 62
Immunomedics, Inc. 63
Idera Pharmaceuticals, Inc. 64
TG Therapeutics, Inc. 65
Curis, Inc. 66
Accentia Biopharmaceuticals, Inc. 67
Portola Pharmaceuticals, Inc. 68
Mundipharma International Limited 69
Pharmacyclics, Inc. 70
Dynavax Technologies Corporation 71
MorphoSys AG 72
BioInvent International AB 73
Xenetic Biosciences plc 74
Takara Bio Inc. 75
Panacea Biotec Limited 76
Transgene Biotek Limited 77
Spectrum Pharmaceuticals, Inc. 78
Affimed Therapeutics AG 79
CIMAB S.A. 80
Supratek Pharma Inc. 81
Memgen, LLC. 82
Actinium Pharmaceuticals, Inc. 83
Agios Pharmaceuticals, Inc. 84
ProNAi Therapeutics, Inc. 85
Grupo Ferrer Internacional, S.A. 86
Onconova Therapeutics, Inc. 87
Kainos Medicine, Inc. 88
Acetylon Pharmaceuticals, Inc. 89
Taiwan Liposome Company, Ltd. 90
Xcovery, Inc. 91
Pharma Mar, S.A. 92
Bellicum Pharmaceuticals, Inc. 93
Biothera, Inc. 94
Sigma-Tau Pharmaceuticals, Inc 95
EpiZyme, Inc. 96
NuCana BioMed Limited 97
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 98
Biosidus S.A. 99
Otsuka Holdings Co., Ltd. 100
Polaris Group 101
Fountain Biopharma Inc. 102
Karyopharm Therapeutics, Inc. 103
Inbiopro Solutions Pvt. Ltd. 104
Conkwest, Inc. 105
International Biotechnology Center Generium 106
Oncobiologics, Inc. 107
Mission Therapeutics Ltd 108
bioXPRESS Therapeutics SA 109
Avipep Pty Ltd 110
Nordic Nanovector AS 111
Biocad 112
Tolero Pharmaceuticals, Inc. 113
Innovent Biologics, Inc. 114
AbbVie Inc. 115
AlphaMab Co., Ltd 116
Amgen Astellas BioPharma K.K. 117
Non-Hodgkin Lymphoma - Therapeutics Assessment 118
Assessment by Monotherapy Products 118
Assessment by Target 119
Assessment by Mechanism of Action 126
Assessment by Route of Administration 134
Assessment by Molecule Type 137
Drug Profiles 140
dasiprotimut T - Drug Profile 140
procarbazine hydrochloride - Drug Profile 142
rituximab - Drug Profile 143
pixantrone dimaleate - Drug Profile 146
StemEx - Drug Profile 150
obinutuzumab - Drug Profile 152
vincristine sulfate liposomal - Drug Profile 154
lenalidomide - Drug Profile 157
PGG beta-glucan - Drug Profile 160
rituximab biosimilar - Drug Profile 164
veltuzumab - Drug Profile 165
bendamustine - Drug Profile 168
alvocidib hydrocholride - Drug Profile 170
blinatumomab - Drug Profile 171
brentuximab vedotin - Drug Profile 174
mocetinostat - Drug Profile 179
agatolimod sodium - Drug Profile 182
forodesine hydrochloride - Drug Profile 185
ISF-35 - Drug Profile 187
Oncohist - Drug Profile 189
MOR-208 - Drug Profile 191
plitidepsin - Drug Profile 192
copanlisib - Drug Profile 194
atorvastatin calcium - Drug Profile 197
epratuzumab - Drug Profile 198
CTL-019 - Drug Profile 203
pegargiminase - Drug Profile 205
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes - Drug Profile 208
PNT-2258 - Drug Profile 210
GS-9973 - Drug Profile 212
BL-8040 - Drug Profile 213
Iomab-B - Drug Profile 215
abexinostat hydrochloride - Drug Profile 217
dasatinib - Drug Profile 219
IMMU-110 - Drug Profile 222
CC-223 - Drug Profile 224
CD19CAR/Virus Specific T Cells - Drug Profile 225
PRT-2070 - Drug Profile 226
BPX-501 - Drug Profile 227
Betalutin - Drug Profile 228
E-7438 - Drug Profile 230
Minor Histocompatibility Antigen - Drug Profile 232
Chimeric Anti-CD20 Monoclonal Antibody - Drug Profile 233
alisertib - Drug Profile 234
pictilisib - Drug Profile 237
vinorelbine tartrate liposomal - Drug Profile 239
AT-9283 - Drug Profile 241
AT-7519 - Drug Profile 243
SAR-650984 - Drug Profile 246
BI-2536 - Drug Profile 248
SD-101 - Drug Profile 250
darinaparsin - Drug Profile 252
briciclib sodium - Drug Profile 254
IMMU-114 - Drug Profile 255
X-396 - Drug Profile 256
EBV-Specific T-Lymphocytes - Drug Profile 257
LY-2780301 - Drug Profile 259
OPB-51602 - Drug Profile 260
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 261
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 262
alefacept - Drug Profile 263
rituximab biosimilar - Drug Profile 264
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 266
pembrolizumab - Drug Profile 267
PF-05082566 - Drug Profile 269
AMG-319 - Drug Profile 270
IMGN-529 - Drug Profile 271
venetoclax - Drug Profile 272
CC-115 - Drug Profile 275
CC-122 - Drug Profile 276
NUC-1031 - Drug Profile 278
KPT-330 - Drug Profile 280
vincristine sulfate liposomal - Drug Profile 282
Genetically Modified T Cell - Drug Profile 283
TG-1101 + TGR-1202 - Drug Profile 284
LMP-Specific Cytotoxic T Cells - Drug Profile 285
rituximab biosimilar - Drug Profile 286
CST-103 - Drug Profile 287
IMO-4200 - Drug Profile 288
AFM-11 - Drug Profile 290
KML-001 - Drug Profile 291
bendamustine hydrochloride - Drug Profile 293
ricolinostat - Drug Profile 294
rituximab biosimilar - Drug Profile 296
CUDC-907 - Drug Profile 298
AVP-5 - Drug Profile 300
CD19-CAR Gene Therapy - Drug Profile 301
AG-221 - Drug Profile 303
tenatumomab - Drug Profile 305
TBL-0306-L - Drug Profile 306
rituximab biosimilar - Drug Profile 307
FV-162 - Drug Profile 308
Oncology Program - Drug Profile 309
IGN-002 - Drug Profile 310
vinorelbine - Drug Profile 311
rituximab biosimilar - Drug Profile 312
Ritonavir Analogs - Drug Profile 313
FIB-114 - Drug Profile 314
BI-1206 - Drug Profile 315
GNR-022 - Drug Profile 316
FB-811 - Drug Profile 317
rituximab biosimilar - Drug Profile 318
CB-839 - Drug Profile 319
SGN-CD70A - Drug Profile 320
FV-214 - Drug Profile 321
rituximab biosimilar - Drug Profile 322
EPZ-005687 - Drug Profile 323
KN-001 - Drug Profile 325
MN-2 - Drug Profile 326
rituximab biosimilar - Drug Profile 327
Small Molecule for Hematologic Malignancies - Drug Profile 328
KM-301 - Drug Profile 329
IBPM-001-RX - Drug Profile 330
rituximab biosimilar - Drug Profile 331
rituximab biosmiliar - Drug Profile 332
rituximab biosimilar - Drug Profile 333
rituximab biosimilar - Drug Profile 334
Non-Hodgkin Lymphoma - Recent Pipeline Updates 335
Non-Hodgkin Lymphoma - Dormant Projects 434
Non-Hodgkin Lymphoma - Discontinued Products 436
Non-Hodgkin Lymphoma - Product Development Milestones 437
Featured News & Press Releases 437
Appendix 445
Methodology 445
Coverage 445
Secondary Research 445
Primary Research 445
Expert Panel Validation 445
Contact Us 446
Disclaimer 446
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2014 22
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Development by Companies, H1 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2014 32
Comparative Analysis by Late Stage Development, H1 2014 33
Comparative Analysis by Clinical Stage Development, H1 2014 34
Comparative Analysis by Early Stage Development, H1 2014 35
Comparative Analysis by Unknown Stage Development, H1 2014 36
Products under Development by Companies, H1 2014 37
Products under Development by Companies, H1 2014 (Contd..1) 38
Products under Development by Companies, H1 2014 (Contd..2) 39
Products under Development by Companies, H1 2014 (Contd..3) 40
Products under Development by Companies, H1 2014 (Contd..4) 41
Products under Development by Companies, H1 2014 (Contd..5) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 45
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 46
Non-Hodgkin Lymphoma - Pipeline by Biogen Idec Inc., H1 2014 47
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2014 48
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2014 49
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2014 50
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 51
Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2014 52
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 53
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 54
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2014 55
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2014 56
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2014 57
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 58
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 59
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2014 60
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 61
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2014 62
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2014 63
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 64
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2014 65
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2014 66
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 67
Non-Hodgkin Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 68
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2014 69
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2014 70
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 71
Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 72
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2014 73
Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2014 74
Non-Hodgkin Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 75
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 76
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Limited, H1 2014 77
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 78
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2014 79
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2014 80
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2014 81
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H1 2014 82
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2014 83
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2014 84
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2014 85
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 86
Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2014 87
Non-Hodgkin Lymphoma - Pipeline by CIMAB S.A., H1 2014 88
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2014 89
Non-Hodgkin Lymphoma - Pipeline by Memgen, LLC., H1 2014 90
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 91
Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 92
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 93
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 94
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 95
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2014 96
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014 97
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2014 98
Non-Hodgkin Lymphoma - Pipeline by Xcovery, Inc., H1 2014 99
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2014 100
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 101
Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc.., H1 2014 102
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 103
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2014 104
Non-Hodgkin Lymphoma - Pipeline by NuCana BioMed Limited, H1 2014 105
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2014 106
Non-Hodgkin Lymphoma - Pipeline by Biosidus S.A., H1 2014 107
Non-Hodgkin Lymphoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 108
Non-Hodgkin Lymphoma - Pipeline by Polaris Group, H1 2014 109
Non-Hodgkin Lymphoma - Pipeline by Fountain Biopharma Inc., H1 2014 110
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 111
Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 112
Non-Hodgkin Lymphoma - Pipeline by Conkwest, Inc., H1 2014 113
Non-Hodgkin Lymphoma - Pipeline by International Biotechnology Center Generium, H1 2014 114
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics, Inc., H1 2014 115
Non-Hodgkin Lymphoma - Pipeline by Mission Therapeutics Ltd, H1 2014 116
Non-Hodgkin Lymphoma - Pipeline by bioXPRESS Therapeutics SA, H1 2014 117
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H1 2014 118
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector AS, H1 2014 119
Non-Hodgkin Lymphoma - Pipeline by Biocad, H1 2014 120
Non-Hodgkin Lymphoma - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 121
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H1 2014 122
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2014 123
Non-Hodgkin Lymphoma - Pipeline by AlphaMab Co., Ltd, H1 2014 124
Non-Hodgkin Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 125
Assessment by Monotherapy Products, H1 2014 126
Number of Products by Stage and Target, H1 2014 129
Number of Products by Stage and Mechanism of Action, H1 2014 136
Number of Products by Stage and Route of Administration, H1 2014 144
Number of Products by Stage and Molecule Type, H1 2014 147
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 343
Non-Hodgkin Lymphoma - Dormant Projects, H1 2014 442
Non-Hodgkin Lymphoma - Discontinued Products, H1 2014 444
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2014 22
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 33
Comparative Analysis by Clinical Stage Development, H1 2014 34
Comparative Analysis by Early Stage Products, H1 2014 35
Assessment by Monotherapy Products, H1 2014 126
Number of Products by Top 10 Target, H1 2014 127
Number of Products by Stage and Top 10 Target, H1 2014 128
Number of Products by Top 10 Mechanism of Action, H1 2014 134
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 135
Number of Products by Top 10 Route of Administration, H1 2014 142
Number of Products by Stage and Top 10 Route of Administration, H1 2014 143
Number of Products by Top 10 Molecule Type, H1 2014 145
Number of Products by Stage and Top 10 Molecule Type, H1 2014 146
